ROGER STEGMAN, M.D.; RAYMOND ALEXANIAN, M.D.
The frequency of solid tumors was evaluated in 628 consecutive patients with multiple myeloma who had been treated with various melphalan-prednisone combinations. Among those patients who lived at least 2 months, the incidence and diversity of second tumors were similar to those in normal persons of the same age and duration at risk. The diagnosis was usually made within 2 years after the start of chemotherapy for the myeloma. Long-term melphalan therapy did not seem to contribute to the pathogenesis of second solid tumors in patients with multiple myeloma.
STEGMAN R, ALEXANIAN R. Solid Tumors in Multiple Myeloma. Ann Intern Med. ;90:780–782. doi: 10.7326/0003-4819-90-5-780
Download citation file:
© 2018
Published: Ann Intern Med. 1979;90(5):780-782.
DOI: 10.7326/0003-4819-90-5-780
Hematology/Oncology, Multiple Myeloma.
Results provided by: